Literature DB >> 204151

Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients.

R Winsnes.   

Abstract

During a period of 2 1/2 years 190 children have been prophylactically treated with zoster immunoglobulin in norway. Information on 130 (68%) of these children was obtained. This group included patients suffering from leukemia, lymphoma, and other malignant disorders, and patients with autoimmune diseases, with impaired immune mechanisms or with for other reasons increased frequency of infections, as well as premature and weak newborns, and infants born to mothers who developed varicella during the last 4 days before delivery. Of the patients who received zoster immunoglobulin within 3 days after exposure, 2.9% developed weak symptoms of varicella. When zoster immunoglobulin was administered 4-5 days after exposure, 37.5% contracted varicella, and when given more than 5 days after exposure, 50% developed the disease. The 9 neonates with possible intrauterine exposure are not included in these figures.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 204151     DOI: 10.1111/j.1651-2227.1978.tb16280.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  5 in total

1.  Chickenpox pneumonia: experience with antiviral treatment.

Authors:  R N Davidson; W Lynn; P Savage; M H Wansbrough-Jones
Journal:  Thorax       Date:  1988-08       Impact factor: 9.139

2.  Nosocomial varicella. Part II: suggested guidelines for management.

Authors:  G F Hayden; J D Meyers; R E Dixon
Journal:  West J Med       Date:  1979-04

3.  Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.

Authors:  F Gigliotti; J A Wiley; A G Harmsen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

4.  Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.

Authors:  Myron J Levin; Jennifer M Duchon; Geeta K Swamy; Anne A Gershon
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

5.  Updated recommendations for use of VariZIG--United States, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-07-19       Impact factor: 17.586

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.